Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Impact of Factor Viii and Von Willebrand Factor Plasma Levels on Cerebral Venous and Sinus Thrombosis: Are They Independent Risk Factors? Publisher Pubmed



Shahsavarzadeh T1 ; Javanmard SH3 ; Saadatnia M1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Alzahra Hospital, Isfahan, Sofeh Street, Iran
  2. 2. Isfahan Medical Education Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Physiology, Isfahan Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: European Neurology Published:2011


Abstract

Background: The aim of this study was to assess the plasma levels of factor VIII (FVIII), von Willebrand factor (vWF) and their association in patients with cerebral venous sinus thrombosis (CVST). Methods: We prospectively included 25 CVST patients admitted to the university hospital and 53 voluntary subjects as a control group. FVIII and vWF were measured after 6 months when anticoagulant therapy was stopped. Results: The mean FVIII and vWF levels were significantly higher in the CVST group compared to the control group (126.21 ± 54.69 vs. 91.9 ± 48.8 IU/dl; p = 0. 012; 157.05 ± 107.74 vs. 94 ± 84%; p = 0.01, respectively). Using analyses calculating the 95th percentile cut-off values, we found high levels of FVIII in patients compared to controls (29.2 vs. 5%; p = 0.01) and the odds ratio with 95% confidence interval (CI) was 7.82 (1.46, 41.6). After adjustment for vWF levels, sex and age, the risk remained significantly increased and the odds ratio with 95% CI was 10.5 (1.1, 101.4) (p = 0.041). Conclusion: FVIII is one of the most prevalent risk factors of CVST and may be associated with an approximately tenfold increased risk for developing CVST. This effect is independent of vWF levels; however, vWF is not an independent risk factor of CVST. Copyright © 2011 S. Karger AG.
Related Docs
View other Related Docs
1. Factor V Leiden, Factor V Cambridge, Factor Ii Ga20210, and Methylenetetrahydrofolate Reductase in Cerebral Venous and Sinus Thrombosis: A Case-Control Study, Journal of Research in Medical Sciences (2015)
2. Evaluation of Rivaroxaban Versus Warfarin for the Treatment of Cerebral Vein Thrombosis: A Case-Control Blinded Study, Current Journal of Neurology (2021)
3. The Prediction Role of D-Dimer in Recurrence of Venous Thromboembolism 1-Year After Anticoagulation Discontinuing Following Idiopathic Deep Vein Thrombosis, Journal of Research in Medical Sciences (2014)
4. The Metabolic Syndrome and the Risk of Cerebral Venous and Sinus Thrombosis: A Case–Control Study, Neurology Asia (2022)
5. Soluble Thrombomodulin and Endothelial Cell Protein C Receptor Levels in Patients With Cerebral Venous and Sinus Thrombosis, European Neurology (2013)
6. Sex Differences in Cerebral Venous Sinus Thrombosis After Adenoviral Vaccination Against Covid-19, European Stroke Journal (2023)
7. The Predictive Factors of Recurrent Deep Vein Thrombosis, ARYA Atherosclerosis (2011)
8. Genotypes of European and Iranian Patients With Type 3 Von Willebrand Disease Enrolled in 3Winters-Ips, Blood Advances (2021)
Experts (# of related papers)
View all Related Experts
Mohammad Saadatnia (14)
Marzieh Tajmirriahi (4)
Other Related Docs
9. Malignant Cutaneous Melanoma Associated With Cerebral Venous Sinus Thrombosis, Neurosciences (2010)
10. On-Admission Versus In-Hospital Thromboembolism Due to Covid-19 Infection. What Is the Particular Characteristic of Those With Early Thrombotic Events?, Advances in Respiratory Medicine (2021)
11. Cerebral Vein and Dural Sinus Thrombosis in Adults in Isfahan, Iran: Frequency and Seasonal Variation, Acta Neurologica Scandinavica (2008)
12. Bleeding Symptoms in Patients Diagnosed As Type 3 Von Willebrand Disease: Results From 3Winters-Ips, an International and Collaborative Cross-Sectional Study, Journal of Thrombosis and Haemostasis (2020)
13. The Frequency of Antithrombotic Therapy in Management of Non-Valvular Atrial Fibrillation in Hospitalized Patients, Journal of Isfahan Medical School (2023)
14. Predictors of Cerebral Venous Thrombosis and Arterial Ischemic Stroke in Young Asian Women, Journal of Stroke and Cerebrovascular Diseases (2012)
15. The Association of Non-O Blood Group and Severity of Liver Fibrosis in Patients With Chronic Hepatitis C Infection, Journal of Research in Medical Sciences (2012)
16. Genetic Thromboembolic Risk Factors Associated With Deep Vein Thrombosis in a Iranian Population, Journal of Isfahan Medical School (2011)
17. Are Cerebral Veins Hounsfield Unit and H: H Ratio Calculating in Unenhanced Ct Eligible to Diagnosis of Acute Cerebral Vein Thrombosis?, Journal of Research in Medical Sciences (2019)
18. Anticoagulant Therapy for Ischemic Stroke: A Review of Literature, Journal of Research in Medical Sciences (2012)
19. Enoxaparin Initiation After Chronic Subdural Haematoma Evacuation: A Randomized Clinical Trial on Timing and Outcomes, Surgical Practice (2023)
20. The Impact of Prothrombin (G20210a) Gene Mutation on Stroke in Youths, ARYA Atherosclerosis (2012)
21. The Evaluation of Left Ventricular Diastolic Dysfunction in Patients With Non-Hemorrhagic Stroke and Atrial Fibrillation, ARYA Atherosclerosis (2017)
22. Cerebral Venous Sinus Thrombosis Risk Factors, International Journal of Stroke (2009)
23. Asian Study of Cerebral Venous Thrombosis, Journal of Stroke and Cerebrovascular Diseases (2019)
24. Hormonal Contraceptives As a Risk Factor for Cerebral Venous and Sinus Thrombosis, Acta Neurologica Scandinavica (2007)
25. Is Thromboprophylaxis Effective in Reducing the Pulmonary Thromboembolism?, ARYA Atherosclerosis (2012)
26. Oral Contraceptive Misuse As a Risk Factor for Cerebral Venous and Sinus Thrombosis, Journal of Research in Medical Sciences (2012)
27. A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor, Clinical and Applied Thrombosis/Hemostasis (2016)
28. Predictive Factors of Deep Vein Thrombosis in Patients Admitted to Intensive Care Unit, Tehran University Medical Journal (2021)
29. Antithrombotic Therapy in Atrial Fibrillation Associated With Valvular Heart Disease: Executive Summary of a Joint Consensus Document From the European Heart Rhythm Association (Ehra) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the Esc Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (Cassa), Heart Rhythm Society (Hrs), Asia Pacific Heart Rhythm Society (Aphrs), South African Heart (Sa Heart) Association and Sociedad Latinoamericana De Estimulacion Cardiaca Y Electrofisiologia (Soleace), Thrombosis and Haemostasis (2017)
30. A Systematic Review on Post-Discharge Venous Thromboembolism Prophylaxis in Patients With Covid-19, Egyptian Heart Journal (2023)
31. Seizure in Cerebral Venous and Sinus Thrombosis, Epilepsia Open (2018)
32. A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency, Clinical and Applied Thrombosis/Hemostasis (2015)
33. A Review of Pathophysiological Mechanism, Diagnosis, and Treatment of Thrombosis Risk Associated With Covid-19 Infection, IJC Heart and Vasculature (2022)